RBC Expects Slowdown in Galderma's Q2 Sales Growth; Price Target, Estimates Revised
() -- RBC Capital Markets anticipates a deceleration in Galderma Group's (GALD.SW) second-quarter constant-currency sales growth, as the research firm adjusted its price target and earnings forecasts for the Swiss dermatology company. "We update our Galderma model ahead of Q2/H1 results (23rd July) and the CMD (planned